GRAIL, Inc.
Grail, Inc. (NASDAQ: GRAL) operates as an innovative commercial-stage healthcare company focused on early cancer detection through multi-cancer early detection testing. The company's mission centers on detecting cancer early, when it can be cured, by shifting the paradigm in cancer screening at population scale. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GRAIL, Inc. does
In the company’s own words
Grail, Inc. (NASDAQ: GRAL) operates as an innovative commercial-stage healthcare company focused on early cancer detection through multi-cancer early detection testing. The company's mission centers on detecting cancer early, when it can be cured, by shifting the paradigm in cancer screening at population scale.
The company's flagship product is Galleri, a multi-cancer early detection test that screens for many types of cancer from a simple blood draw. Galleri can detect cancer signals across more than 50 types of cancer and accurately predict the specific organ or tissue type where the cancer signal originated, known as Cancer Signal of Origin, with high positive predictive values and low false positive rates. As of December 31, 2025, Grail has sold more than 475,000 commercial tests, including more than 185,000 tests in 2025. The company has established commercial partnerships with leading healthcare systems, employers, digital health platforms, payors, and life insurance providers.
Grail has conducted what it believes is the largest clinical program in genomic medicine to date, collecting population-scale clinical data from more than 385,000 participants across nine clinical studies. The company's clinical program includes over 180,000 patients enrolled in PATHFINDER and PATHFINDER 2 clinical studies and the NHS-Galleri Trial. In January 2026, Grail submitted a premarket approval application to the FDA to support broad access for Galleri in the United States. The company is also enrolling up to 50,000 Medicare beneficiaries in its REACH study to evaluate Galleri's clinical impact among Medicare beneficiaries and historically underserved communities.
Beyond asymptomatic screening, Grail leverages its proprietary targeted methylation platform for additional applications across the cancer care continuum, including precision oncology partnerships with biopharmaceutical companies. The company launched its research use only targeted methylation platform with customizable classifiers in 2023.
Grail operates a high-capacity laboratory accredited by the College of American Pathologists and certified by CLIA and the New York State Department of Health. The company has begun entering select international markets through distributor partners and intends to expand through partnerships including Samsung. The company's website is www.grail.com.
Company details
- Sector
- Healthcare
- Industry
- Health Services
- Headquarters
- SUNNYVALE, CA
- Fiscal year end
- December
- CIK
- 1699031
- SIC
- 8071
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GRAIL, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GRAIL, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GRAIL, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GRAIL, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GRAIL, Inc.'s last four quarterly filings that the numbers alone won't show?”